Platinum
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Platinum
- Molecular weight
- 195.08
- Structure (SMILES)
These details could not be displayed.
- albumin bound paclitaxel and platinum
- c i 77795
- C.i. 77795
- metallic platinum
- Metallic platinum
- platina l
- Platina l
- platinum
- Platinum
- platinum (cisplatin or carboplatin)
- Platinum (cisplatin or carboplatin)
- PLATINUM [HSDB]
- PLATINUM [MART.]
- PLATINUM [MI]
- Platinum [WHO-DD]
- platinum black
- Platinum black
- platinum elemental
- platinum hsdb
- platinum mart
- platinum metallicum
- Platinum metallicum
- PLATINUM METALLICUM [HPUS]
- platinum metallicum hpus
- platinum mi
And 10 more, listed on the interactive page.
- CAS registry numbers
- 7440-06-4
- ChEMBL ID
- CHEMBL1235478
- InChIKey
- BASFCYQUMIYNBI-UHFFFAOYSA-N
- PubChem compound IDs
- 23939
- RxNorm IDs (RxCUI)
- 1311280
- FDA ingredient codes (UNII)
- 49DFR088MY
- First in class
- No
- Orphan designation
- No
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Hypopharyngeal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002938
- Subject identifier
- D007012
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003869
- Subject identifier
- D001943
- Condition
- Triple Negative Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005537
- Subject identifier
- D064726
- Condition
- Salivary Gland Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0000521
- Subject identifier
- D012468
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002974
- Subject identifier
- D002583
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0007576
- Subject identifier
- D004938
- Condition
- Lung Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0008903
- Subject identifier
- D008175
- Condition
- Lung Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0021117
- Subject identifier
- D008175
- Condition identifier
- EFO_0000571
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002938
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001901
- Condition identifier
- MONDO_0000521
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002087
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002158
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002367
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002898
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003001
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0003960
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004116
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004608
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004958
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004986
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005002
- Condition identifier
- MONDO_0005036
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005061
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005096
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005097
- Highest recorded phase
- 2
And 30 more, listed on the interactive page.
- Event
- acute lymphocytic leukaemia
- Reports
- 3
- Reporting signal score
- 12.0567
- Event
- anaemia
- Reports
- 3,577
- Reporting signal score
- 2,295.45
- Event
- anaphylactic shock
- Reports
- 6
- Reporting signal score
- 15.0128
- Event
- blood electrolytes decreased
- Reports
- 2
- Reporting signal score
- 9.36591
- Event
- bone marrow failure
- Reports
- 977
- Reporting signal score
- 1,165.35
- Event
- dehydration
- Reports
- 2,224
- Reporting signal score
- 1,556.74
- Event
- disease progression
- Reports
- 1,976
- Reporting signal score
- 1,612.01
- Event
- escherichia bacteraemia
- Reports
- 2
- Reporting signal score
- 7.77157
- Event
- febrile neutropenia
- Reports
- 3,989
- Reporting signal score
- 6,565.79
- Event
- haematotoxicity
- Reports
- 694
- Reporting signal score
- 1,211.53
- Event
- hepatitis
- Reports
- 8
- Reporting signal score
- 21.0354
- Event
- hepatotoxicity
- Reports
- 7
- Reporting signal score
- 19.3724
- Event
- hypertension
- Reports
- 8
- Reporting signal score
- 8.13007
- Event
- hypokalaemia
- Reports
- 1,191
- Reporting signal score
- 997.599
- Event
- hypomagnesaemia
- Reports
- 622
- Reporting signal score
- 775.446
- Event
- hypophysitis
- Reports
- 2
- Reporting signal score
- 7.10918
- Event
- immune-mediated renal disorder
- Reports
- 1
- Reporting signal score
- 7.02934
- Event
- leukopenia
- Reports
- 1,455
- Reporting signal score
- 1,258.53
- Event
- malignant neoplasm progression
- Reports
- 1,839
- Reporting signal score
- 1,972.33
- Event
- metastases to central nervous system
- Reports
- 3
- Reporting signal score
- 8.21539
- Event
- mucosal inflammation
- Reports
- 1,582
- Reporting signal score
- 2,395.2
- Event
- myelosuppression
- Reports
- 760
- Reporting signal score
- 1,280.53
- Event
- nausea
- Reports
- 4,898
- Reporting signal score
- 834.79
- Event
- nephropathy toxic
- Reports
- 3
- Reporting signal score
- 7.29253
- Event
- neutropenia
- Reports
- 4,281
- Reporting signal score
- 4,379.41
And 14 more, listed on the interactive page.
- NCT00807066
- NCT01844791
- NCT04338620
- NCT05296278
- NCT02489409
- NCT02815592
- NCT05844150
- NCT03567642
- NCT03607539
- NCT03731442
- NCT04420884
- NCT04502641
- NCT06151743
- NCT06128460
- NCT06145308
- NCT06355024
- NCT06355037
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- Yes
- Heavy atoms
- 1
- Molecular formula
- Pt
- Monoisotopic mass
- 194.964794
- Natural product
- Yes
Related records
Trials (268)
- A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
- A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma
- A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
- A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
- A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour
- A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
- A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC
- A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
- A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC
- A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.
- A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC
- A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
- A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
- A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.
- A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
- A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer
- A Study Assessing the Safety of Cord Blood Product in Sacroiliac Joint Syndrome (SIJ)
- A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)
- A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
In development for (11)
- Breast neoplasm Phase 2
- Cervical cancer Phase 2
- Esophageal cancer Phase 3
- Hypopharyngeal carcinoma Phase 3
- Lung cancer Phase 3
- Lung neoplasm Phase 3
- Neoplasm Phase 1
- Non-small cell lung carcinoma Phase 3
- Salivary gland carcinoma Phase 2
- Small cell lung carcinoma Phase 2
- Triple-negative breast carcinoma Phase 2